Literature DB >> 17451465

Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA.

Bo Jin1, Richard Y Wang, Qi Qiu, Fuminaka Sugauchi, Teresa Grandinetti, Harvey J Alter, J Wai-Kuo Shih.   

Abstract

Double-stranded RNA is produced during virus replication and, together with the viral antigen, is responsible for inducing host antivirus immunity. The hepatitis C virus (HCV) non-structural protein-3 (NS3) has been implicated in the immune evasion of HCV, and is one of the prime targets for inducing immunity against HCV infection. Mice were immunized with recombinant NS3 protein (rNS3) and poly (I:C) emulsified in Montanide ISA 720 (M720). Cytokine production was assayed by enzyme-linked immunospot assay, and CD4(+) IFN-gamma(+) T helper (Th) cells or CD8(+) IFN-gamma(+) cytotoxic T lymphocytes were detected by flow cytometry. Anti-NS3 titre and immunoglobulin G2a (IgG2a) and IgG1 levels were monitored by enzyme-linked immunosorbent assay. Administration of rNS3 formulated in poly (I:C) and M720 induced anti-NS3 titres with a predominantly IgG2a isotype comparable to those induced by rNS3 in CpG-ODN and M720. The cytokine profiles showed that this formulation induced a Th1-biased immune response with several-fold more interferon-gamma (IFN-gamma)-producing cells than interleukin-4-producing cells. In contrast, rNS3 in M720 induced a Th2-biased immune response. The frequency of IFN-gamma-producing CD4(+) and CD8(+) cells induced by rNS3 in poly (I:C) and M720 was significantly higher than that induced by rNS3, rNS3 in M720, or rNS3 in poly (I:C), and was comparable to that induced by rNS3 in CpG-ODN with M720. The antigen-specific CD8(+) T-cell immune response persisted for up to 7 months after immunization. In conclusion, poly (I:C) with rNS3 in M720 can elicit a strong and persistent Th1-biased immune response and a cytotoxic T-lymphocyte response through cross-priming in mice. This study highlighted a promising formulation for inducing an efficient cellular immune response against HCV that has potential for HCV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451465      PMCID: PMC2265985          DOI: 10.1111/j.1365-2567.2007.02607.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice.

Authors:  Nicolaos Avramidis; Panayiotis Victoratos; Minas Yiangou; L Hadjipetrou-Kourounakis
Journal:  Vet Microbiol       Date:  2002-09-24       Impact factor: 3.293

Review 2.  The burden of hepatitis C in the United States.

Authors:  W Ray Kim
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.

Authors:  Masahiro Yamamoto; Shintaro Sato; Kiyotoshi Mori; Katsuaki Hoshino; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

Review 4.  Adjuvants designed for veterinary and human vaccines.

Authors:  J Aucouturier; L Dupuis; V Ganne
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

Review 5.  Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines.

Authors:  R De Francesco; P Neddermann; L Tomei; C Steinkühler; P Gallinari; A Folgori
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

6.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

7.  Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.

Authors:  Laura Arribillaga; Ascensión López Díaz de Cerio; Pablo Sarobe; Noelia Casares; Marta Gorraiz; Africa Vales; Oscar Bruna-Romero; Francisco Borrás-Cuesta; Glaucia Paranhos-Baccala; Jesús Prieto; Juan Ruiz; Juan José Lasarte
Journal:  Vaccine       Date:  2002-12-13       Impact factor: 3.641

8.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

9.  TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.

Authors:  Hiroyuki Oshiumi; Misako Matsumoto; Kenji Funami; Takashi Akazawa; Tsukasa Seya
Journal:  Nat Immunol       Date:  2003-01-21       Impact factor: 25.606

10.  Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization.

Authors:  Xuanmao Jiao; Richard Y-H Wang; Zhiming Feng; Harvey J Alter; James Wai-Kuo Shih
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

View more
  12 in total

1.  CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.

Authors:  Sandra Lazzaro; Cinzia Giovani; Simona Mangiavacchi; Diletta Magini; Domenico Maione; Barbara Baudner; Andrew J Geall; Ennio De Gregorio; Ugo D'Oro; Cecilia Buonsanti
Journal:  Immunology       Date:  2015-08-28       Impact factor: 7.397

2.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Authors:  Kristina E Rehm; Rachel L Roper
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

3.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

Review 4.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

5.  Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-Induced mice acute viral myocarditis.

Authors:  Qing Kong; Weifeng Wu; Fan Yang; Yanli Liu; Yimin Xue; Mengsha Gao; Wenyin Lai; Xiaofen Pan; Yuluan Yan; Yu Pang; Yuanhua Deng
Journal:  Virol J       Date:  2012-10-11       Impact factor: 4.099

6.  IL-9 Inhibits Viral Replication in Coxsackievirus B3-Induced Myocarditis.

Authors:  Miao Yu; Qi Long; Huan-Huan Li; Wei Liang; Yu-Hua Liao; Jing Yuan; Xiang Cheng
Journal:  Front Immunol       Date:  2016-10-06       Impact factor: 7.561

7.  Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8(+) T cells against Listeria monocytogenes in the murine infection model.

Authors:  Mohammed Bahey-El-Din; Pat G Casey; Brendan T Griffin; Cormac G M Gahan
Journal:  Vaccine       Date:  2008-08-06       Impact factor: 3.641

8.  Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Authors:  Jeffrey A Lyon; Evelina Angov; Michael P Fay; JoAnn S Sullivan; Autumn S Girourd; Sally J Robinson; Elke S Bergmann-Leitner; Elizabeth H Duncan; Christian A Darko; William E Collins; Carole A Long; John W Barnwell
Journal:  PLoS One       Date:  2008-07-30       Impact factor: 3.240

9.  Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.

Authors:  Anshu Malik; Manish Gupta; Rajesh Mani; Himanshu Gogoi; Rakesh Bhatnagar
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

10.  Association between the interferon-γ +874T/A polymorphism and susceptibility to hepatitis B virus infection: a meta-analysis.

Authors:  Liang Li
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.